Monoclonal gammopathy in lymphoma.
Monoclonal gammopathy in lymphoma.
复制标题
DOI：
10.1001/archinte.1975.00330010064009
复制
发表时间：
1975
影响因子：
--
通讯作者：
R. Alexanian
中科院分区：
文献类型：
--
作者：
R. Alexanian
在1,682例淋巴瘤患者中，68%的患者进行了血清蛋白电泳。在400例慢性淋巴细胞白血病和淋巴细胞淋巴瘤患者中，2.3%的患者出现IgG峰，其频率显著高于同龄正常人。IgM峰值出现在4.5%的淋巴瘤患者，其特征是弥漫性淋巴结组织学浸润。该频率比预测的高约100倍，表明通过电泳检测到的大多数IgM峰由淋巴瘤产生。治疗的临床反应与肿瘤质量的减少相关，通常为治疗前水平的10%至50%。慢性淋巴细胞性白血病和淋巴细胞性淋巴瘤患者需要更大幅度的肿瘤缩小以改善缓解期。
Serum protein electrophoresis was performed in 68% of 1,682 consecutive patients with lymphoma. Of 400 patients with chronic lymphocytic leukemia and lymphocytic lymphoma, 2.3% had an IgG peak, a frequency significantly higher than that found in normal individuals of comparable age. IgM peaks occurred in 4.5% of patients with lymphomas characterized by diffuse histologic infiltration of lymph nodes. This frequency was about 100 times greater than predicted and indicated that most IgM peaks detected by electrophoresis are produced by lymphomas. Clinical responses to therapy were associated with reductions of tumor mass usually ranging from 10% to 50% of the pretreatment level. A much greater magnitude of tumor reduction is needed to improve remission duration for patients with chronic lymphocytic leukemia and lymphocytic lymphoma.